BreastArchives
Highlights of the San Antonio breast cancer symposium 2025 (Part 2)
Breast 1 min.
The annual San Antonio Breast Cancer Symposium (SABCS) combines the principles of multidisciplinary management, with the basic science underlying pathobiological processes in breast cancer. The 48th meeting was held at the Henry B Gonzales Convention Center in downtown San Antonio, Texas, United States...
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China
Breast 1 min.
Robust pharmacoeconomic evidence regarding the long-term affordability of sacituzumab tirumotecan (sac-TMT) in treatment of metastatic triple-negative breast cancer (TNBC) remains lacking. We evaluated the cost-effectiveness of sac-TMT versus chemotherapy for previously treated metastatic TNBC from the...
LncRNA HAR1A in triple-negative breast cancer: mechanisms and the role of polymorphism rs 6089838 in susceptibility
Breast 1 min.
Long non-coding RNAs (lncRNAs) are increasingly recognized as crucial regulators and potential biomarkers in triple-negative breast cancer (TNBC). This study examined the link between the rs6089838 polymorphism in HAR1A and TNBC susceptibility/progression and function. 197 TNBC patients and 185 healthy...
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer
Breast 1 min.
Metastatic breast cancer is a heterogeneous disease entity with varying genomic alterations. Mutations may be acquired through tumor evolution under the pressure of treatment. While both tumor tissue genotyping and cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) may be used to identify actionable...
